Reduction in tenderness and/or nipple sensitivity.
Product information
Batch #
470757
Usage details
What was your goal when starting this product?
My goal was estrogen receptor modulation, specifically to address symptoms consistent with mild gynecomastia and to manage estrogen-related side effects during hormonal fluctuations. I chose raloxifene because it acts as a selective estrogen receptor modulator (SERM), blocking estrogen effects in breast tissue while preserving beneficial estrogen activity in other tissues.
How did you use this product?
Dosage: 60 mg daily
Frequency: Once per day
Timing: Morning with food for consistency
Adjustments:
Maintained a consistent dose throughout use
No loading phase or tapering
Total duration of use
8 weeks total, followed by reassessment.
Did you stack it with other compounds?
Test C - 400-700 per week
Results & effectiveness
What changes did you notice while using this product?
Reduction in tenderness and/or nipple sensitivity.
How soon did you start noticing effects?
Reduction in tenderness or sensitivity: within 2–3 weeks Visible changes in tissue firmness/fullness: 4–8 weeks, gradual No noticeable systemic hormonal fluctuations
How did the results compare to your expectations?
Results were in line with expectations. Raloxifene appeared to reduce sensitivity and prevent progression of glandular tissue. Changes were gradual rather than dramatic, which aligns with its mechanism of action.
Side effects & tolerance
Did you experience any side effects or negative changes?
Occasional mild hot flashes
Slight leg cramps during the first weeks
No mood instability or libido changes
Injection pain / discomfort (if applicable)
Not applicable/taken orally.
Overall tolerance
Tolerance was good. The medication was easy to incorporate into a daily routine, and side effects were mild and transient.
Final thoughts
Would you use this product again? Why or why not?
Yes, it appears effective for managing estrogen receptor activity in target tissues with a relatively favorable side-effect profile compared to more aggressive interventions.
Would you recommend this product to others?
Individuals with early-stage gynecomastia
Those needing estrogen receptor modulation during TRT/cycle
It should be avoided by:
Individuals with a history of blood clots or thromboembolic events